194357-64-7
194357-64-7
Chemical Structure
NSP-DMAE-NHS
- CAS No.: 194357-64-7
- Formula:C30H26N2O9S
- Molecular Weight:590.60
IUPAC Name: 3-(9-((4-(((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl)-2,6-dimethylphenoxy)carbonyl)acridin-10-ium-10-yl)propane-1-sulfonate
InChIKey: AAYSIOJYGRABGS-UHFFFAOYSA-N
SMILES: O=C(C1=CC(C)=C(OC(C2=C3C=CC=CC3=[N+](CCCS(=O)([O-])=O)C4=C2C=CC=C4)=O)C(C)=C1)ON5C(CCC5=O)=O
Biological Activity: NSP-DMAE-NHS is an acridinium ester-based signal amplifier that can act as a luminescent probe to effectively improve the detection performance of biosensors. NSP-DMAE-NHS preserves the biochemical activity of biomolecules during the conjugation process. NSP-DMAE-NHS has been successfully applied to label mouse anti-human PI3 monoclonal antibodies for chemiluminescent immunoassays, as well as for pre-competitive chemiluminescent immunochromatographic detection of TP53 fusion proteins. NSP-DMAE-NHS can be used in detection studies of cancer and related biomarkers[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NSP-DMAE-NHS | 99.48% | NSP-DMAE-NHS is an acridinium ester-based signal amplifier that can act as a luminescent probe to effectively improve the detection performance of biosensors. NSP-DMAE-NHS preserves the biochemical activity of biomolecules during the conjugation process. NSP-DMAE-NHS has been successfully applied to label mouse anti-human PI3 monoclonal antibodies for chemiluminescent immunoassays, as well as for pre-competitive chemiluminescent immunochromatographic detection of TP53 fusion proteins. NSP-DMAE-NHS can be used in detection studies of cancer and related biomarkers. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NSP-DMAE-HEG-Giu-NHS | NSP-DMAE-HEG-Giu-NHS (Fig.18) is an activated labeling reagent containing acridine ester, and it is a key component of Cyclosporine A (HY-B0579) tracers. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-TAMRA-SE | 96.95% | 5-TAMRA-SE is an amine-reactive fluorescent agent, and its conjugate produces bright, pH-insensitive orange-red fluorescence with good photostability (Ex/Em = 565/580 nm). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NSP-AS | 98.83% | NSP-AS is chemiluminescent acridinium substrate II and can be used in homo geneous assays. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
NSP-SA-NHS | 98.38% | NSP-SA-NHS is an acridinium ester that can be used for chemiluminescent immunoassay. A rapid and sensitive chemiluminescent immunoassay of Bisphenol A (BPA) with NSP-SA-NHS-labeled has been developed. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Carboxyrhodamine 6G succinimidyl ester | 5-Carboxyrhodamine 6G succinimidyl ester (R6G-SE) is an amine reactive fluorescent dye. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Rhodamine B NHS ester | 99.87% | Rhodamine B NHS ester (N-Hydroxysuccinimidyl rhodamine B ester) is an amine-reactive fluorescent probe (λex/λem: 564/589 nm, respectively). Rhodamine B NHS ester could react with Glycine (HY-Y0966). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
5-Carboxyrhodamine 110 NHS ester | 5-Carboxyrhodamine 110 NHS Ester is the nonsulfonated analog of the BP Fluor 488 dye. The amine-reactive 5(6)-Carboxyrhodamine 110 NHS Ester can be used to create bright and photostable green-fluorescent bioconjugates with excitation/emission maxima ~502/527 nm. For many applications, the dye is preferred over 5-(6)-carboxyfluorescein NHS ester or FITC because of its exceptional photostability and fluorescence insensitivity to pH (4-9). Although the mixed isomers of Carboxyrhodamine 110 NHS Ester preferred, routinely used fluorescent dye for labeling proteins, peptides and nucleotides, purification of peptide and nucleotides labeled with 5(6) isomers might be troublesome due to significant signal broadening in HPLC purification. Peptides and nucleotides labeled with a single isomer usually give better resolution in HPLC purification that is often required in the conjugation processes. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
10-Methyl-9-(phenoxycarbonyl)acridinium fluorosulfonate | 99.79% | 10-Methyl-9-(phenoxycarbonyl)acridinium fluorosulfonate, a phenyl ester of acridinium esters, is a fluorescent dye that produces chemiluminescent under neutral conditions. 10-Methyl-9-(phenoxycarbonyl)acridinium fluorosulfonate can be used for the measurement of hydrogen peroxide. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
10-Methyl-9-(phenoxycarbonyl) acridinium trifluoromethanesulfonate | 99.41% | 10-Methyl-9-(phenoxycarbonyl) acridinium trifluoromethanesulfonate is an acridinium ester that produces fluorescent 10-methyl-9-acridone upon oxidation with hydrogen peroxide, persulfate, and other oxidants under alkaline conditions. 10-Methyl-9-(phenoxycarbonyl) acridinium trifluoromethanesulfonate can be used in chemiluminescent assays, enzyme, antigen, antibody, and hormone immunoassays, and for the detection of oxidants in environmental, biological, and pharmaceutical samples. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acridinium C2 NHS ester | 92.11% | Acridinium C2 NHS ester is a chemiluminescent label that is active for the development of protein and nucleic acid probes. Acridinium C2 NHS ester can be used in bioanalysis and diagnostics to provide highly sensitive detection solutions. Acridinium C2 NHS ester is widely used in medical research, especially in the monitoring and analysis of biomolecules. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Wang L, et al. Development of a Competitive Chemiluminescent Assay for Quantitative Determination of TP53 Fusion Protein Using Reagent Strips. Appl Biochem Biotechnol. 2024;196(9):6315-6329. [Content Brief]
- [2]. Xu M, et al. Systematic analysis of serum peptidase inhibitor 3 in psoriasis diagnosis and treatment. Clin Rheumatol. 2024;43(11):3361-3372. [Content Brief]
